Vas Narasimhan (Simon Dawson/Bloomberg via Getty Images)
As Sandoz waits for Novartis to determine its fate, the generics player buys out a respiratory device company
While Novartis chief Vas Narasimhan mulls whether or not the pharma will sell off Sandoz, the giant generics drug subsidiary is still trucking along like …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
